Characteristics and 2-Year Outcomes of Dabigatran Treatment in Patients with Heart Failure and Atrial Fibrillation: GLORIA-AF — Sérgio Dubner (2020) | RDL Network
Characteristics and 2-Year Outcomes of Dabigatran Treatment in Patients with Heart Failure and Atrial Fibrillation: GLORIA-AF
Article 2020 en
Authors
SD
Sérgio Dubner
CT
Christine Teutsch
MH
Menno V. Huisman
Abstract
1 min read
Patients with AF and history of HF may have greater disease burden at AF diagnosis and increased mortality rates vs. patients without HF. Stroke and major bleeding rates were roughly comparable between groups confirming the long-term safety and effectiveness of dabigatran in patients with HF.
Sake J. van der Wall, Christine Teutsch, Sérgio Dubner, Hans‐Christoph Diener, Jonathan L. Halperin, Chang Sheng, Kenneth J. Rothman, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Professor Gregory Lip, Menno V. Huisman
Sérgio Dubner, Menno V. Huisman, Hans‐Christoph Diener, Jonathan L. Halperin, Kenneth J. Rothman, Sara Bozzinì, Jutta Bergler‐Klein, Kristina Zint, Lionel Riou França, Shihai Lu, Christine Teutsch, Miney Paquette, Professor Gregory Lip
Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Professor Gregory Lip
Discussion(0)
No comments yet. Be the first to comment.